ACHN - ACHN Stock Extends Rally: Soars 55% in 2 Sessions

ACHN stock has been on a roll for two days straight after Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) announced positive updates from the Phase 1 study of its product ACH-5228, an experimental oral factor D inhibitor.

The announcement was made on Monday, and soon after, the stock climbed by as much as 16.50% to close the session at $2.77. However, the climb yesterday was not a one-off, and the stock regained its momentum on Tuesday morning, as it soared another 33% once the markets opened today.

That being said, some may wonder ...